As GSK’s HIV unit ViiV Healthcare grapples with a new rival in the injectable HIV prevention and treatment field, the company is reinforcing the staying power of its long-acting treatment Cabenuva | ...
IMPAACT 2017 (MOCHA) week 96 results show long-acting Cabenuva (cabotegravir + rilpivirine) effectively maintained viral suppression in 94.4% of adolescents aged 12 to <18 years Additional paediatric ...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today ...
The federal Food and Drug Administration has approved Cabenuva, the first complete long-acting injectable HIV regimen that does not require daily pills. It is approved for people with an undetectable ...
To make Cabenuva the standard treatment option for HIV, Johnson & Johnson and GSK-owned ViiV Healthcare must first dethrone Gilead Sciences’ once-daily stalwart Biktarvy. Now, the partners have a ...
Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine ...
Long-acting cabotegravir/rilpivirine (Cabenuva; CAB/RPV-LA) appeared superior to daily oral antiretroviral therapy (ART) in maintaining viral load suppression for ...
FRANKFURT (Reuters) - GlaxoSmithKline's HIV business ViiV is within weeks of resubmitting its request for approval of its long-acting injection Cabenuva to U.S. drug regulators, ViiV's head of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results